2024-09-16 - Analysis Report
## Gilead Sciences, Inc. (GILD) Stock Analysis

**Company Overview:** Gilead Sciences, Inc. is a biopharmaceutical company that develops and commercializes medicines in areas of unmet medical need, including HIV/AIDS, viral hepatitis, oncology, and inflammation.

**Performance Analysis:**

**1. Return Performance:**

* GILD has accumulated a return of 19.94%, while the S&P 500 (VOO) has gained 88.73%.
* This represents a significant underperformance of -68.79% relative to the S&P 500.
* The current relative divergence is at the 21.24% percentile, meaning that its underperformance is higher than 78.76% of the time.

**2. Recent Price Movement:**

* **Closing Price:** $82.81
* **5-day Moving Average:** $81.5
* **20-day Moving Average:** $78.28
* **60-day Moving Average:** $74.19

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 78.59, indicating the stock is in overbought territory.
* **PPO (Percentage Price Oscillator):** 0.42, suggesting potential for upward price movement.
* **Delta_Previous_Relative_Divergence:** 8.12, indicating a recent short-term upward trend.
* **Expected Return:** 19.96%, representing the maximum expected return over 5 years.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

* The most recent earnings (2024-08-08) show an EPS of 1.29, exceeding expectations.
* This indicates a positive trend in the company's profitability.

**Overall Analysis:**

Gilead Sciences is currently experiencing an overbought technical condition with a recent surge in price momentum. Although the stock has significantly underperformed the S&P 500, recent earnings beat expectations, hinting at potential improvement in profitability. Investors may consider the stock as a potential investment opportunity given the strong earnings and technical indicators, but they should also be aware of the elevated risk associated with the stock's current overbought status. It is advisable to monitor the stock closely to understand its potential impact on the overall portfolio. 
